| Multiple Myeloma |
1 |
0.96 |
| CAR-T |
0 |
0.9 |
| Biologic Therapy |
0 |
0.82 |
| T-Lymphocyte |
0 |
0.72 |
| Cytokines |
0 |
0.18 |
| Toxicology |
0 |
0.18 |
| Antigens |
0 |
0.11 |
| Neurotoxicity |
0 |
0.11 |
| Plasma |
0 |
0.11 |
| Stem Cell Research and Therapy |
0 |
0.11 |
| Tumor |
0 |
0.09 |
| Bone Marrow |
0 |
0.08 |
| Blood |
0 |
0.07 |
| Depression |
0 |
0.06 |
| Bone |
0 |
0.05 |
| Anaphylaxis |
0 |
0.04 |
| Chemotherapy |
0 |
0.04 |
| Graft |
0 |
0.04 |
| Graft Versus Host Disease |
0 |
0.04 |
| Graft Versus Host Disease and Transplant Complications |
0 |
0.04 |
| Proteasome Inhibitor |
0 |
0.04 |
| Residual Disease |
0 |
0.04 |
| Acute Leukemia |
0 |
0.03 |
| Acute Lymphoblastic Leukemia |
0 |
0.03 |
| B-Cell Lymphoma |
0 |
0.03 |
| Cell Transplantation |
0 |
0.03 |
| Cerebral Edema |
0 |
0.03 |
| Gastrointestinal Hemorrhage |
0 |
0.03 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.03 |
| Quality of Life |
0 |
0.03 |
| Aphasia |
0 |
0.02 |
| Aspergillosis |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Delirium |
0 |
0.02 |
| Drug Resistance |
0 |
0.02 |
| Edema |
0 |
0.02 |
| Encephalopathy |
0 |
0.02 |
| Europe |
0 |
0.02 |
| Flow Cytometry |
0 |
0.02 |
| Food and Drug Administration (FDA) |
0 |
0.02 |
| Fungal Infection |
0 |
0.02 |
| Hand |
0 |
0.02 |
| Hematologic Malignancies |
0 |
0.02 |
| Hematology |
0 |
0.02 |
| Hemorrhage |
0 |
0.02 |
| Hospital |
0 |
0.02 |
| Immunotherapy |
0 |
0.02 |
| Leukemia |
0 |
0.02 |
| Lymphocytes |
0 |
0.02 |
| Lymphohistiocytosis |
0 |
0.02 |
| Lymphoma |
0 |
0.02 |
| Memory |
0 |
0.02 |
| Opportunistic Infection |
0 |
0.02 |
| Pharmacokinetics |
0 |
0.02 |
| Prognosis |
0 |
0.02 |
| Receptors |
0 |
0.02 |
| Refractory |
0 |
0.02 |
| Remission |
0 |
0.02 |
| Respiratory Failure |
0 |
0.02 |
| Seizure |
0 |
0.02 |
| Suicide |
0 |
0.02 |
| Transplantation |
0 |
0.02 |
| Traumatic Brain Injury |
0 |
0.02 |
| Tremor |
0 |
0.02 |